Estudo randomizado | Fentermina/topiramato para tratamento de obesidade na adolescência.

Phentermine/Topiramate for the Treatment of Adolescent Obesity – NEJM Evidence

Comentário no Twitter

This RCT evaluated phentermine/topiramate in adolescents ages 12 to <17 yrs with high BMIs over a 56 week period. At both mid- and top-doses, treatment significantly reduced BMI and waist circumference compared to placebo. https://t.co/HbCZOAlZPf@PedsEndoSociety #PedsEndo2022 pic.twitter.com/nB5juqxyA0

— NEJM Evidence (@NEJMEvidence) April 30, 2022